Preventing and treating biologic-associated opportunistic infections.

Kevin Winthrop, Tom Chiller

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

A variety of opportunistic pathogens have been reported to infect patients receiving tumor necrosis factor (TNF) antagonists for the treatment of autoimmune diseases. These pathogens are numerous, and include coccidioides, histoplasma, nontuberculous mycobacteria, Mycobacteria tuberculosis, and others of public health concern. Accordingly, TNF antagonists should be used with caution in patients at risk for tuberculosis, and screening for latent tuberculosis infection should be undertaken before anti-TNF therapy is initiated. Although screening and prevention efforts have decreased the risk of tuberculosis in this setting, optimal screening methods represent an area of evolving controversy. This article discusses the latest developments in screening methodologies for latent tuberculosis infection, as well as potential preventive and therapeutic considerations for opportunistic infections associated with anti-TNF agents and other biologic therapies.

Original languageEnglish (US)
Pages (from-to)405-410
Number of pages6
JournalNature reviews. Rheumatology
Volume5
Issue number7
DOIs
StatePublished - Jul 2009

Fingerprint

Opportunistic Infections
Biological Products
Tumor Necrosis Factor-alpha
Latent Tuberculosis
Tuberculosis
Coccidioides
Histoplasma
Nontuberculous Mycobacteria
Biological Therapy
Mycobacterium tuberculosis
Autoimmune Diseases
Therapeutics
Public Health

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Preventing and treating biologic-associated opportunistic infections. / Winthrop, Kevin; Chiller, Tom.

In: Nature reviews. Rheumatology, Vol. 5, No. 7, 07.2009, p. 405-410.

Research output: Contribution to journalArticle

@article{78ad82d452f34cfc92f92c7cd6da917c,
title = "Preventing and treating biologic-associated opportunistic infections.",
abstract = "A variety of opportunistic pathogens have been reported to infect patients receiving tumor necrosis factor (TNF) antagonists for the treatment of autoimmune diseases. These pathogens are numerous, and include coccidioides, histoplasma, nontuberculous mycobacteria, Mycobacteria tuberculosis, and others of public health concern. Accordingly, TNF antagonists should be used with caution in patients at risk for tuberculosis, and screening for latent tuberculosis infection should be undertaken before anti-TNF therapy is initiated. Although screening and prevention efforts have decreased the risk of tuberculosis in this setting, optimal screening methods represent an area of evolving controversy. This article discusses the latest developments in screening methodologies for latent tuberculosis infection, as well as potential preventive and therapeutic considerations for opportunistic infections associated with anti-TNF agents and other biologic therapies.",
author = "Kevin Winthrop and Tom Chiller",
year = "2009",
month = "7",
doi = "10.1038/nrrheum.2009.105",
language = "English (US)",
volume = "5",
pages = "405--410",
journal = "Nature Reviews Rheumatology",
issn = "1759-4790",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Preventing and treating biologic-associated opportunistic infections.

AU - Winthrop, Kevin

AU - Chiller, Tom

PY - 2009/7

Y1 - 2009/7

N2 - A variety of opportunistic pathogens have been reported to infect patients receiving tumor necrosis factor (TNF) antagonists for the treatment of autoimmune diseases. These pathogens are numerous, and include coccidioides, histoplasma, nontuberculous mycobacteria, Mycobacteria tuberculosis, and others of public health concern. Accordingly, TNF antagonists should be used with caution in patients at risk for tuberculosis, and screening for latent tuberculosis infection should be undertaken before anti-TNF therapy is initiated. Although screening and prevention efforts have decreased the risk of tuberculosis in this setting, optimal screening methods represent an area of evolving controversy. This article discusses the latest developments in screening methodologies for latent tuberculosis infection, as well as potential preventive and therapeutic considerations for opportunistic infections associated with anti-TNF agents and other biologic therapies.

AB - A variety of opportunistic pathogens have been reported to infect patients receiving tumor necrosis factor (TNF) antagonists for the treatment of autoimmune diseases. These pathogens are numerous, and include coccidioides, histoplasma, nontuberculous mycobacteria, Mycobacteria tuberculosis, and others of public health concern. Accordingly, TNF antagonists should be used with caution in patients at risk for tuberculosis, and screening for latent tuberculosis infection should be undertaken before anti-TNF therapy is initiated. Although screening and prevention efforts have decreased the risk of tuberculosis in this setting, optimal screening methods represent an area of evolving controversy. This article discusses the latest developments in screening methodologies for latent tuberculosis infection, as well as potential preventive and therapeutic considerations for opportunistic infections associated with anti-TNF agents and other biologic therapies.

UR - http://www.scopus.com/inward/record.url?scp=70349577776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349577776&partnerID=8YFLogxK

U2 - 10.1038/nrrheum.2009.105

DO - 10.1038/nrrheum.2009.105

M3 - Article

C2 - 19568254

AN - SCOPUS:70349577776

VL - 5

SP - 405

EP - 410

JO - Nature Reviews Rheumatology

JF - Nature Reviews Rheumatology

SN - 1759-4790

IS - 7

ER -